CLINICAL–LIVER, PANCREAS, AND BILIARY TRACT Long-Term Benefit of Interferon ! Therapy of Chronic Hepatitis D: Regression of Advanced Hepatic Fibrosis

PATRIZIA FARCI,* TANIA ROSKAMS,‡ LUCHINO CHESSA,* GIOVANNA PEDDIS,* ANNA PAOLA MAZZOLENI,* ROSETTA SCIOSCIA,* GIANCARLO SERRA,* MARIA ELIANA LAI,* MAURIZIO LOY,* LUCIANO CARUSO,§ VALEER DESMET,‡ ROBERT H. PURCELL,! and ANGELO BALESTRIERI* *Dipartimento di Scienze Mediche, Università di Cagliari, Cagliari, Italy; ‡Department of Pathology, University of Leuven, Leuven, Belgium; §Dipartimento di Medicina Interna e Patologie Sistemiche, Università di Catania, Catania, Italy; and !Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

[1]  M. Rizzetto,et al.  Treatment of hepatitis D , 2005, Journal of viral hepatitis.

[2]  G. Lucarelli,et al.  Reversibility of Cirrhosis in Patients Cured of Thalassemia by Bone Marrow Transplantation , 2002, Annals of Internal Medicine.

[3]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[4]  M. Arthur,et al.  Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. , 2002, Gastroenterology.

[5]  I. Wanless.  Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. , 2001, Journal of clinical gastroenterology.

[6]  D. Valla,et al.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. , 2001, The New England journal of medicine.

[7]  M. Sherman,et al.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. , 2000, Archives of pathology & laboratory medicine.

[8]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[9]  J. Iredale,et al.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.

[10]  M. Rizzetto,et al.  Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon‐treated patients and in patients who underwent liver transplantation , 1998, Hepatology.

[11]  M. Kaplan,et al.  Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis , 1997, Annals of Internal Medicine.

[12]  M. Kaplan,et al.  Sustained Biochemical and Histologic Remission of Primary Biliary Cirrhosis in Response to Medical Treatment , 1997, Annals of Internal Medicine.

[13]  A. Andriulli,et al.  The predominance of hepatitis delta virus genotype I among chronically infected Italian patients , 1997, Hepatology.

[14]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[15]  P. van Eyken,et al.  Treatment of chronic hepatitis D with interferon alfa-2a. , 1994, The New England journal of medicine.

[16]  J. Casey,et al.  A genotype of hepatitis D virus that occurs in northern South America. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Friedman.  The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies , 1993 .

[18]  R. Purcell,et al.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. , 1991, The New England journal of medicine.

[19]  M. Brook,et al.  Treatment of hepatitis. , 1988, The Journal of hospital infection.

[20]  M. Rizzetto,et al.  Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. , 1986, JAMA.

[21]  M. Rizzetto,et al.  Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. , 1983, Annals of internal medicine.

[22]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[23]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[24]  M. Kaplan,et al.  Is liver fibrosis reversible? , 2001, The New England journal of medicine.

[25]  E. Sagnelli,et al.  Decrease in HDV endemicity in Italy. , 1997, Journal of hepatology.

[26]  A. Elzouki,et al.  Hepatitis D Virus , 2018, Definitions.

[27]  J. Hoofnagle.  Therapy of acute and chronic viral hepatitis. , 1994, Advances in internal medicine.

[28]  S. Friedman.  Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. , 1993, The New England journal of medicine.

[29]  H. Handa,et al.  Hepatitis Delta Virus , 2006 .

[30]  S. Hadziyannis.  Use of alpha-interferon in the treatment of chronic delta hepatitis. , 1991, Journal of hepatology.

[31]  M. Brunetto,et al.  Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. , 1987, Journal of hepatology.